In order to establish the environmental impact of an active pharmaceutical ingredient (API), 15 good information on the level of exposure in surface waters is needed. Exposure 16 concentrations are typically estimated using information on the usage of an API as well as 17 removal rates in the patient, the wastewater system and in surface waters. These input data 18 are often highly variable and difficult to obtain, so model estimates often do not agree with 19 measurements made in the field. In this paper we present an approach which uses inverse 20 modelling to estimate overall removal rates of pharmaceuticals at the catchment scale using a 21 hydrological model as well as prescription and monitoring data for a few representative sites 22 for a country or region. These overall removal rates are then used to model exposure across 23 the broader landscape. Evaluation of this approach for APIs in surface waters across England 24
for a country or region. These overall removal rates are then used to model exposure across 23 the broader landscape. Evaluation of this approach for APIs in surface waters across England 24
and Wales showed good agreement between modelled exposure distributions and available 25 monitoring data. Use of the approach, alongside estimates of predicted no-effect 26 concentrations for the 12 study compounds, to assess risk of the APIs across the UK 27 landscape, indicated that, for most of the compounds, risks to aquatic life were low. 28
However, ibuprofen was predicted to pose an unacceptable risk in 49.5% of the river reaches 29 studied. For diclofenac, predicted exposure concentrations were also compared to the 30 Environmental Quality Standard previously proposed by the European Commission and 4.5% 31 of river reaches were predicted to exceed this concentration. While the current study focused 32 on pharmaceuticals, the approach could also be valuable in assessing the risks of other 'down 33 the drain' chemicals and could help inform our understanding of the important dissipation 34 processes for pharmaceuticals in the pathway from the patient to ecological receptors. 35
Introduction

41
During the life cycle of a pharmaceutical product, Active Pharmaceutical Ingredients (APIs) 42 2010a and b; Janna et al., 2011) and so only the parts salient to this analysis will be described 141
here. LF2000-WQX is the water quality extension model to the Low Flows 2000 (LF2000) 142 software system (Young et al., 2003; Environment Agency, 2004) , which is a geographical 143 information system (GIS) based decision support tool designed to estimate river flows at 144 ungauged sites. It combines hydrological models estimating the magnitude and variability of 145 flows across a catchment with a water quality model. The water quality model is driven by 146 discharges from sewage treatment plants (STPs), the locations of which are preset in the 147 model along with data describing the population served, treatment type and dry weather flow 148 of each works. The outputs of the model are mean and 90th and 95th percentile 149 concentrations for each river reach within the catchment being modelled. 150
Calculation of concentrations in river reaches is based on a simple mass balance mixing 151 equation which is applied in an iterative Monte Carlo simulation using the method of 152 combining distributions proposed by Warn and Brew (Warn and Brew, 1980) . Point-source 153 effluent emissions are combined with reach-specific flow statistics to calculate in-river 154 concentrations after mixing at the point of discharge, allowing for upstream concentrations of 155 the pharmaceutical. Flow in the river and flow volume from the sewage works are described 156 as distributions. The other parameters are held constant. The river flow is characterised as 157 log-normal and the sewage works flows as normal. Changes in concentration with 'flow time' 158 due to dilution, from e.g. inputs from tributaries, and degradation also are calculated. 159
The emissions of an API for a given STP are typically derived from prescription data and 160 value for an API at each of the study sites by the predicted mean value for the specific site. 201
To allow comparison of the inverse modelling removal estimates with removal estimates 202 from the 'standard' forward approach to API exposure modelling, removal percentages were 203 also calculated for each of the monitoring study sites based on published data on metabolism, 204 removal in treatment and dissipation in surface waters (Table 3) . Where a range of values 205 were reported for these input parameters, lowest and highest values were used to produce 206 'worst' and 'best' case estimates of removal. For use in broader modelling, a correction was 207 made, using dissipation data from for each sampling point and these mean MECs were then collated into one single distribution 220 using the approach described by Straub (2008) and Metcalfe et al. (2008) . Median and upper 221 and lower quartiles were derived for the concentration distributions. Concentrations of 222 monitored APIs were then estimated for all river reaches in the monitored catchments using 223 the mean, minimum and maximum removal rates that were derived from the inverse 224 modelling and corrected for in stream dissipation. Concentration distributions and associated 225 summary statistics from the monitoring data analyses and the modelling were then compared. 226 227
Assessment of pharmaceutical risks to aquatic systems in England and Wales 228
The average, maximum and minimum removal estimates and corrected for in-stream 229 dissipation data were then used in the LF2000-WQX model to predict concentrations of the 230 12 study APIs in 3117 river reaches distributed across 22 large catchments in England and 231
Wales serving a population of 21 million people. Annual mean predicted environmental 232 concentrations (PECs) were obtained for each pharmaceutical for every reach in each 233
catchment. 234
To assess the implications of the predicted exposure distributions in terms of ecological risks, 235 data on the acute and chronic (growth and reproduction) toxicity of the study APIs to algae, 236 invertebrates and fish were extracted from the literature (Table 5 ). With the exception of 237 naproxen, these data were used to derive predicted no-effect concentrations (PNECs) for each 238 study pharmaceutical using assessment factors recommended by the European Chemicals Table 6 ). Concentrations of cyclophosamide, 262 fluoxetine, ketoprofen, orlistat and simvastatin were below detection limits in the monitoring 263 study, so it was only possible to estimate a minimum removal rate for these substances -264 these were all greater than 95.5% (Table 6 ). In comparison, estimates of effective removal,based on forward modelling using data on usage, metabolism and dissipation in wastewater 266 treatment and surface waters resulted in 'worst' case estimates of between 4 (atenolol) and 267 97.1% (naproxen) and 'best' case estimates of between 70.2 (trimethoprim) and 99.8% 268 (ibuprofen) removal between use by the patient and the sampling points for the four study 269 sites (Table 6 ). Mean percentage removal values for carbamazepine, diclofenac, fluoxetine, 270 furosemide and trimethoprim, obtained from usage, metabolism and wastewater and surface 271 water dissipation data were lower than removal values obtained using inverse modelling of 272 the monitoring data and for selected compounds (e.g. trimethoprim), there was a large 273 difference between the two approaches. Due to a lack of data, it was not possible to estimate 274 removal percentages for cyclophosphamide, ketroprofen, orlistat and simvastatin using the 275 forward modelling approach. 276
Correction of the inverse modelling data for in-stream dissipation of the study compounds 277 indicated that on average between 90.01 (atenolol) and 99.84% (ibuprofen) is removed 278 between the point of prescription/use and the points of emission from treatment plants within 279 the monitoring study catchments (Table 6 ). With the exception of atenolol where on average 280 3% of the compound was estimated to have dissipated in the rivers within the catchment, in-281 stream dissipation was found to actually play a negligible role in the overall dissipation of the 282 study compounds and the monitoring sites. Never-the-less, the corrected values were 283 employed in the subsequent landscape scale exposure modelling. 284 285
Comparison of exposure predictions against monitoring data 286
It was possible to obtain good datasets on mean concentrations of atenolol, carbamazepine, 287 diclofenac, ibuprofen and trimethoprim in surface waters at different points within 10 288 catchments allowing concentration distributions to be derived (Figure 1) . Mean, minimum 289
and maximum estimated removal rates between the point of use and emission to surface 290 waters were used in the LF2000-WQX model to estimate mean concentrations of the study 291 compounds for every river reach in the 10 monitored catchments in England and Wales. 292
Summary statistics for the distributions of mean predicted concentrations for all river reaches 293 in the monitored catchments, obtained from the modelling, are shown in Table 7 . With the 294 exception of ibuprofen, there was good agreement between the monitored and modelled 295 distributions (Table 7 ; Figure 1 ). For ibuprofen, the modelled median concentrations and 296 upper and lower quartiles for the distributions were substantially smaller than the summary 297 statistic values obtained from monitoring studies. 298 299
Assessment of risks of APIs to surface waters in England and Wales 300
To assess the implications of the distributions of concentrations of the APIs, concentrations 301 were used alongside ecotoxicity data to characterise the level of risk posed by each API in 302 each of the river reaches modelled. Risk characterisation ratios for the study APIs for the 22 303 catchments (Figure 2) show that, for trimethoprim, furosemide, diclofenac and atenolol, 304
RCRs were 0.008 or lower, indicating that these substances pose a very low risk to aquatic 305 systems in England and Wales (Figure 2A ). While the maximum RCRs of greater than one 306 were obtained for carbamazepine, fluoxetine and simvastatin in one of the 3312 river reaches 307 and for orlistat in 12 river reaches, simvastatin exceeded one, in the vast majority of reaches a 308
RCRs were lower than one indicating that these substances generally pose an acceptable risk 309 to the aquatic environment. For orlistat, simvastatin and fluoxetine, exposure estimates are 310 based on limits of detection so in reality RCRs will be lower still. However, the maximum 311 RCR for ibuprofen was 174 and, for this compound, 49.5% of river reaches across the 22 312 catchments were predicted to be at risk. When the catchments were considered individually 313 the EQS is based and it is possible that the EQS is overly conservative. 375
With the exception of ibuprofen, where a risk was identified for 49.5% of river reaches, 376
RCRs for the other study compounds in river reaches in England and Wales were generally 377 lower than one (for carbamazepine, orlisat, fluoxetine and simvastatin a risk was identified in 378 one, one and 12 of the 3312 river reaches respectively), indicating that the other compounds 379 pose an acceptable risk to the UK environment. The findings for ibuprofen agree with 380 conclusions from other studies into the risks of APIs in aquatic systems, where ibuprofen has 381 been highlighted as a drug of potential concern in river systems (Christensen et al., 2009; 382 Lienert et al., 2007). We would therefore advocate that further work is carried out to explore 383 the wider occurrence of ibuprofen in surface waters in England and Wales and to explore 384 whether effects are occurring in the catchments where a significant proportion of river 385 reaches are predicted to be at risk; the PNEC may also need to be re-assessed as well. 386
Comparison of exposure predictions for diclofenac with the previously proposed EQS for 387 diclofenac, indicated that 4.5% of river reaches would have exceeded the EQS had it been 388
adopted. This percentage is in agreement with the value of 3-5% previously predicted for
EQS exceedences in rivers in England using the forward modelling approach (Johnson et al., 390 2013). 391
Overall, this study demonstrates the potential of using inverse modelling alongside 392 monitoring data to generate model input data in exposure and risk assessment. As a total 393 removal rate is estimated for a broad scale, the approach offers a number of advantages, i.e. it 394 takes into account factors such as the non-use of prescribed drugs by patients; it addresses 395 differences in metabolism across the population; it accounts for dissipation processes in the 396 local sewerage network and it accounts for differences in effectiveness of different 397 wastewater treatment technologies in a catchment. The four study sites used in this study 398
were based in four different counties located in the South East and Midland regions of 399
England so the approach appears to be effective at estimating exposure for different regions 400 in a country the size of England. This is backed up by the comparisons of exposure 401 predictions for the catchments that have been monitored in England and Wales with the 402 experimentally-derived data. 403
The approach is, however, reliant on the availability of good quality monitoring data and 404 cannot be applied to compounds that are not yet in use. Cultural and demographic differences 405 might mean that the total removal predictions from this study cannot be applied to other 406 countries. However, there is no reason why a similar monitoring and modelling strategy to 407 that employed in the current study could not be applied elsewhere in order to generate state-408 or country-specific removal rates and hence assess the broad scale exposure risks of APIs in 409 other regions of the world. The concept could also be applied at different stages in the 410 pathway of a pharmaceutical from the patient to environmental receptors to better understand 411 key dissipation processes for pharmaceuticals to inform future modelling initiatives. 
